For the maintenance treatment of patients with COPD. Not a rescue inhaler. Not for asthma. LABA monotherapy associated with increased risk of serious asthma-related events. Due to overdose risk, don’t use with LABA-containing medicines. Don’t initiate in acutely deteriorating COPD. More serious or fatal course of chickenpox or measles can occur in susceptible patients. Taper patients slowly when transferring from systemic corticosteroids due to risk of impaired adrenal function. Discontinue immediately if paradoxical bronchospasm, anaphylaxis, or other hypersensitivity reactions occur. Don’t use if allergic to product components.
©2021 AstraZeneca. All rights reserved. US-58152 Last Updated 10/21